RxDoctor Payments Data

John Perl, MD

Neuroradiology · Boise, IDNPI 1518906312

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,660 of the $19,291 with a category attached, or 81.2%. Stryker accounts for 87.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $16,492 and has fallen 97.2% since, to $454 in 2025.

$19,291in general payments, 2019–2025

Across 81 payments — averaging $238.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$17K
  • Microvention, Inc.$661
  • Medtronic$659
  • Siemens Medical Solutions USA, Inc.$359
  • Qapel Medical Inc$283
  • Johnson & Johnson$203
  • plus $288 from 3 others
$6,316in research payments, 2019–2025

Across 6 payments — averaging $1052.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Stryker$6K
$13,087in ownership & investment interests, 2019–2025

Across 5 payments — averaging $2617.38 each. An ownership or investment interest held by the physician or an immediate family member.

  • Centerline Biomedical Inc.$13K

What the payments were for

  • Consulting fees$15,66081%
  • Travel & lodging$4242%
  • Food & beverage$3,20717%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuroradiology providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$77,785
Medicare patients
180
Services billed
415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate36$174

Paid to pharmacies, not to this prescriber.

Other neuroradiology in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →